General Information of Drug Combination (ID: DCRSKBT)

Drug Combination Name
Emtricitabine Raltegravir
Indication
Disease Entry Status REF
Primary Biliary Cholangitis Phase 2 [1]
Component Drugs Emtricitabine   DMBMUWZ Raltegravir   DMYURI6
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Emtricitabine
Disease Entry ICD 11 Status REF
Hepatitis virus infection 1E50-1E51 Approved [2]
Human immunodeficiency virus infection 1C62 Approved [2]
Hepatitis B virus infection 1E51.0 Phase 3 [3]
Emtricitabine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Modulator [2]
------------------------------------------------------------------------------------
Emtricitabine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [5]
------------------------------------------------------------------------------------
Emtricitabine Interacts with 3 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Decreases Expression [6]
Albumin (ALB) OTVMM513 ALBU_HUMAN Affects Binding [7]
Deoxycytidine kinase (DCK) OTW8HLZC DCK_HUMAN Affects Binding [8]
------------------------------------------------------------------------------------
Indication(s) of Raltegravir
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [4]
Raltegravir Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human immunodeficiency virus Integrase (HIV IN) TT5FH9Y POL_HV1B1 Modulator [4]
------------------------------------------------------------------------------------
Raltegravir Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [10]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [11]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03954327) Combination Antiretroviral Therapy (cART) for PBC
2 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3 Clinical pipeline report, company report or official report of Gilead (2011).
4 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
5 Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017 Jan;47(1):77-85.
6 Chronic Nucleoside Reverse Transcriptase Inhibitors Disrupt Mitochondrial Homeostasis and Promote Premature Endothelial Senescence. Toxicol Sci. 2019 Dec 1;172(2):445-456. doi: 10.1093/toxsci/kfz203.
7 Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. doi: 10.1080/15216540400016286.
8 Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides. J Med Chem. 2007 Jun 28;50(13):3004-14. doi: 10.1021/jm0700215. Epub 2007 May 27.
9 Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother. 2012 Jun;56(6):2959-66. doi: 10.1128/AAC.05424-11. Epub 2012 Feb 27.
10 Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen. Drug Metabol Drug Interact. 2011;26(3):139-41.
11 Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Ther Drug Monit. 2010 Dec;32(6):782-6.